1. Supplementary Tables 1-6 from Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort
- Author
-
Renée T. Fortner, Rudolf Kaaks, Elio Riboli, Melissa Merritt, Sabina Rinaldi, Mark Gunter, Laure Dossus, Ruth Travis, Kay Tee Khaw, Pilar Amiano, Eva Ardanaz, Maria-Dolores Chirlaque, Maria-José Sánchez, Antonio Agudo, Elisabete Weiderpass, Petra H. Peeters, Carla H. van Gils, H.B(as). Bueno-de-Mesquita, Carlotta Sacerdote, Rosario Tumino, Amalia Mattiello, Valeria Pala, Domenico Palli, Antonia Trichopoulou, Eleni-Maria Papatesta, Pagona Lagiou, Heiner Boeing, Marina Kvaskoff, Mathilde His, Marie-Christine Boutron-Ruault, Anne Tjønneland, Marianne Holm, Kim Overvad, Theron Johnson, Helena Schock, and Danja Sarink
- Abstract
Supplementary table 1. Correlations of sRANKL and the sRANKL/OPG ratio with select hormones among controls: EPIC cohort nested case-control study. Supplementary table 2. Distribution of covariates by quintiles of sRANKL. Supplementary table 3. Circulating concentrations of sRANKL and breast cancer risk by hormone-receptor subtype and menopausal status at blood collection. Supplementary table 4. The sRANKL/OPG ratio and breast cancer risk by hormone-receptor subtype and menopausal status at blood collection. Supplementary table 5. sRANKL additionally adjusted for continuous (log2) OPG and breast cancer risk by hormone-receptor subtype: EPIC nested case-control study. Supplementary table 6. sRANKL/OPG cross-classification based on median split of sRANKL and OPG and breast cancer risk by hormone-receptor subtype: EPIC nested case-control study.
- Published
- 2023